Information:
Fel:
ID
27801
Beskrivning
RATIONALE: Nilotinib and imatinib m esylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well giving nilotinib together with imatinib mesylate works in treating patients with early chronic phase chronic myelogenous leukemia. This is the Concomitant Therapy Form.
Nyckelord
Versioner (1)
- 2017-11-29 2017-11-29 -
Rättsinnehavare
Gruppo Italiano Malattie EMatologiche dell'Adulto
Uppladdad den
29 november 2017
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Concomitant Therapy GIMEMA CML0408 NCT00769327
Similar models
Concomitant Therapy
- StudyEvent: ODM
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
Terapie farmacologiche concomitanti
C1707479 (UMLS CUI-1)
Acronym
Item
Acronimo
integer
C2986333 (UMLS CUI [1])
Start date of administration
Item
Data inizio somministrazione
date
C2826734 (UMLS CUI [1])
End date of administration
Item
Data fine somministrazione
date
C2826744 (UMLS CUI [1])
Drug
Item
Farmaco
text
C0013227 (UMLS CUI [1,1])
C2347852 (UMLS CUI [1,2])
C2347852 (UMLS CUI [1,2])